 |
|
Oncologic Outcome after Cessation or Dose Reduction of Capecitabine in Patients with Colon Cancer
Jung-A Yun, Hee Cheol Kim, Hyun-Sook Son, Hyoung Ran Kim, Hae Ran Yun, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun
J Korean Soc Coloproctol. 2010;26(4):287-292. Published online 2010 Aug 31 DOI: https://doi.org/10.3393/jksc.2010.26.4.287
|
|
Citations to this article as recorded by
 The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients
Doreen Z. Mhandire, Andrew K. L. Goey
Molecular Diagnosis & Therapy.2022; 26(2): 137. CrossRef Global Cancer Burden and Natural Disasters: A Focus on Asia’s Vulnerability, Resilience Building, and Impact on Cancer Care
Roselle De Guzman, Monica Malik
Journal of Global Oncology.2019; (5): 1. CrossRef Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer
Devon J. Boyne, Colleen A. Cuthbert, Dylan E. O’Sullivan, Tolulope T. Sajobi, Robert J. Hilsden, Christine M. Friedenreich, Winson Y. Cheung, Darren R. Brenner
JAMA Network Open.2019; 2(5): e194154. CrossRef 5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line
Jan Hartinger, Pavel Veselý, Martin Šíma, Irena Netíková, Eva Matoušková, Luboš Petruželka
Prague Medical Report.2017; 118(4): 128. CrossRef An exploratory study to identify risk factors for the development of capecitabine‐induced Palmar Plantar Erythrodysesthesia (PPE)
Annie Law, Sue Dyson, Denis Anthony
Journal of Advanced Nursing.2015; 71(8): 1825. CrossRef
|